Cipargamin
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Cipargamin
- Molecular weight
- 390.24
- Structure (SMILES)
- C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc12
- cipargamin
- Cipargamin
- cipargamin [INN]
- Cipargamin [WHO-DD]
- cipargamin inn
- cipargamin who dd
- cipargamina
- Cipargamina
- cipargamine
- Cipargamine
- kae 609
- KAE-609
- kae609
- Kae609
- KAE609
- KAE609 (Cipargamin)
- nitd 609
- NITD-609
- NITD-609, (+)-
- nitd609
- NITD609
- CAS registry numbers
- 1193314-23-6
- ChEMBL ID
- CHEMBL1082723
- InChIKey
- CKLPLPZSUQEDRT-WPCRTTGESA-N
- PubChem compound IDs
- 44469321
- FDA ingredient codes (UNII)
- Z7Q4FWA04P
- Patents
- 0
- Designations
- 2
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- cipargamin
- Type
- Synthetic organic
Mechanisms of action
- Mechanism
- P-type ATPase inhibitor
- Action type
- Inhibitor
- Target
- P-type ATPase
- Protein identifier
- Q27724
Open Targets mechanisms
- Mechanism
- P-type ATPase inhibitor
- Action type
- Inhibitor
- Target
- P-type ATPase
- Condition
- Malaria
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001068
- Subject identifier
- D008288
- Condition
- Malaria, Falciparum
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007444
- Subject identifier
- D016778
- Condition identifier
- EFO_0001068
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005136
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005920
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005921
- Highest recorded phase
- 2
- NCT01524341
- NCT01836458
- NCT03334747
- NCT04321252
- NCT04675931
- NCT02543086
- NCT05750628
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 3
- Polar surface area
- 56.92
- Calculated partition coefficient (ALogP)
- 4.34
- Calculated partition coefficient (XLogP)
- 3.9
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 0
- Heavy atoms
- 26
- Molecular formula
- C19H14Cl2FN3O
- Monoisotopic mass
- 389.0497956
- Natural product
- No
- Recorded assays
- 354
- Active assays
- 65
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (9)
- A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection
- A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection
- Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos
- Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria
- Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.
- Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects
- To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
In development for (2)
- Malaria Phase 2
- Plasmodium falciparum malaria Phase 2